Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.60 |
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30421894 | 1.00 | LMNA (0.71) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30373303 | 0.89 | NR4A2 (0.69) | LMNAKDM4EALDH1A1NR4A2 | |
| SCHEMBL2429622 | 0.89 | NR4A2 (0.69) | LMNAKDM4EALDH1A1NR4A2 | |
| SCHEMBL9029183 | 0.88 | LMNA (0.68) | LMNACHRM1CNR2 | |
| SCHEMBL7914466 | 0.86 | LMNA (0.73) | LMNAKDM4ECHRM1CNR2 | |
| SCHEMBL9026679 | 0.85 | CNR2 (0.74) | LMNACNR2 | |
| Dimethylamine SCHEMBL7778089 | 0.84 | NR4A2 (0.68) | LMNAALDH1A1NR4A2 | |
| SCHEMBL4082279 | 0.84 | CNR2 (0.81) | LMNACNR2 | |
| SCHEMBL22843746 | 0.84 | NR4A2 (0.59) | LMNANR4A2CNR2 | |
| SCHEMBL29398958 | 0.84 | NR4A2 (0.59) | LMNANR4A2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024104344-A1 | QUINOLINECARBOXYLIC ACID DERIVATIVE AND USE THEREOF | 沈阳中化农药化工研发有限公司 | 2024-05-23 | — | — | WO | disclosed |
| CN-118047721-A | Quinoline carboxylic acid derivative and application thereof | 沈阳中化农药化工研发有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-116157392-A | Compounds targeting RNA binding proteins or RNA modification proteins | 雷多纳治疗公司 | 2023-05-23 | — | — | CN | disclosed |
| US-10087144-B2 | Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 H)-quinolone | UCL BUSINESS PLC (GB) | 2018-10-02 | — | — | US | disclosed |
| EP-3145914-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL Business PLC (GB) | 2017-03-29 | — | — | EP | disclosed |
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2017-03-09 | — | — | US | disclosed |
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2017-03-09 | — | — | US | disclosed |
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2017-03-09 | — | — | US | disclosed |
| WO-2015189560-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015189560-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | UCL BUSINESS PLC (GB) | 2015-12-17 | — | — | WO | disclosed |
| US-4954507-A | 1-tertiary-alkyl-substituted naphthyridine carboxylic acid antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0376870-A1 | A new organosilylpolyphosphoric reagent, its preparation and application to the process of synthesis of 3-carboxyquinolones or azaquinolones and their salts | CENTRO MARGA PARA LA INVESTIGACION S.A. (ES) | 1990-07-04 | — | — | EP | disclosed |
| EP-0288519-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | Bristol-Myers Squibb Company (US) | 1988-11-02 | — | — | EP | disclosed |
| EP-0266576-A2 | 1-Tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents | Bristol-Myers Squibb Company (US) | 1988-05-11 | — | — | EP | disclosed |
| WO-1988002627-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-04-21 | — | — | WO | disclosed |
| US-4698350-A | 1-ethyl-6-fluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarboxylic acid and antibacterial use thereof | STERLING DRUG INC. (US) | 1987-10-06 | — | — | US | disclosed |
| EP-0179239-A2 | 7-(Pyridinyl)-/-alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid having antibacterial activity and preparation thereof | STERLING DRUG INC. (US) | 1986-04-30 | — | — | EP | disclosed |
| EP-0168733-A2 | Process for the preparation of quinolinone and naphthyridoncarboxylic acids | BAYER AG (DE) | 1986-01-22 | — | — | EP | disclosed |
| US-4552882-A | 7-(1-Pyrrolyl) derivatives of 1-ethyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids and 1-ethyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids and their use as antimicrobial agents | PROVESAN, SA (CH) | 1985-11-12 | — | — | US | disclosed |
| US-4552882-A | 7-(1-Pyrrolyl) derivatives of 1-ethyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids and 1-ethyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids and their use as antimicrobial agents | PROVESAN, SA (CH) | 1985-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066722-A1 | AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE | CBR3, AGTR1, CBR1 | LMNA 565/4885KDM4E 4288/4885ALDH1A1 3209/4885 |
| US-10087144-B2 | Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 H)-quinolone | AGTR1, CBR3, CBR1 | LMNA 565/4885KDM4E 4318/4885ALDH1A1 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.